Nurix Therapeutics (NASDAQ:NRIX) Price Target Raised to $36.00

Nurix Therapeutics (NASDAQ:NRIX) had its price target raised by HC Wainwright from $35.00 to $36.00 in a research note released on Wednesday,Benzinga reports. They currently have a buy rating on the stock. HC Wainwright also issued estimates for Nurix Therapeutics’ Q1 2025 earnings at ($0.72) EPS, Q2 2025 earnings at ($0.74) EPS, Q3 2025 earnings at ($0.76) EPS, Q4 2025 earnings at ($0.78) EPS and FY2025 earnings at ($3.00) EPS.

NRIX has been the subject of several other research reports. Royal Bank of Canada decreased their price objective on Nurix Therapeutics from $27.00 to $26.00 and set an “outperform” rating for the company in a report on Monday, October 14th. BMO Capital Markets assumed coverage on shares of Nurix Therapeutics in a research report on Friday, December 6th. They issued an “outperform” rating and a $35.00 price target on the stock. BTIG Research assumed coverage on shares of Nurix Therapeutics in a report on Tuesday, December 10th. They issued a “buy” rating and a $35.00 price objective for the company. Jefferies Financial Group began coverage on shares of Nurix Therapeutics in a report on Friday, October 11th. They set a “buy” rating and a $41.00 target price on the stock. Finally, Stifel Nicolaus raised their price target on Nurix Therapeutics from $34.00 to $36.00 and gave the stock a “buy” rating in a report on Wednesday. One analyst has rated the stock with a hold rating and sixteen have given a buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $30.71.

Nurix Therapeutics Stock Performance

Shares of NRIX stock opened at $19.71 on Wednesday. Nurix Therapeutics has a 52 week low of $7.79 and a 52 week high of $29.56. The firm’s 50-day simple moving average is $20.09 and its two-hundred day simple moving average is $22.39. The firm has a market cap of $1.50 billion, a price-to-earnings ratio of -6.82 and a beta of 2.14.

Nurix Therapeutics (NASDAQ:NRIX) last posted its quarterly earnings data on Tuesday, January 28th. The company reported ($0.75) EPS for the quarter, missing the consensus estimate of ($0.67) by ($0.08). Nurix Therapeutics had a negative net margin of 354.85% and a negative return on equity of 63.38%. Analysts forecast that Nurix Therapeutics will post -2.73 earnings per share for the current year.

Insider Transactions at Nurix Therapeutics

In related news, CFO Houte Hans Van sold 2,811 shares of the stock in a transaction on Thursday, January 30th. The stock was sold at an average price of $19.85, for a total value of $55,798.35. Following the transaction, the chief financial officer now owns 39,549 shares of the company’s stock, valued at $785,047.65. This represents a 6.64 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Gwenn Hansen sold 3,690 shares of Nurix Therapeutics stock in a transaction dated Thursday, January 30th. The stock was sold at an average price of $19.85, for a total value of $73,246.50. Following the sale, the insider now directly owns 55,937 shares of the company’s stock, valued at approximately $1,110,349.45. This trade represents a 6.19 % decrease in their position. The disclosure for this sale can be found here. Insiders own 7.20% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of NRIX. Amalgamated Bank boosted its stake in shares of Nurix Therapeutics by 30.6% in the 3rd quarter. Amalgamated Bank now owns 2,182 shares of the company’s stock valued at $49,000 after purchasing an additional 511 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its stake in Nurix Therapeutics by 31.6% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,330 shares of the company’s stock worth $54,000 after purchasing an additional 559 shares during the last quarter. Quarry LP boosted its position in Nurix Therapeutics by 3,746.2% during the third quarter. Quarry LP now owns 2,500 shares of the company’s stock valued at $56,000 after buying an additional 2,435 shares during the period. International Assets Investment Management LLC grew its stake in shares of Nurix Therapeutics by 1,098.4% during the third quarter. International Assets Investment Management LLC now owns 4,494 shares of the company’s stock valued at $101,000 after buying an additional 4,119 shares during the last quarter. Finally, Quest Partners LLC increased its holdings in shares of Nurix Therapeutics by 21.3% in the third quarter. Quest Partners LLC now owns 7,458 shares of the company’s stock worth $168,000 after buying an additional 1,312 shares during the period.

About Nurix Therapeutics

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.